66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). - Ambrosini, M.; Tougeron, D.; Modest, D.P.; Guimbaud, R.; Kopetz, S.; Decraecker, M.; Sclafani, F.; Coutzac, C.; Lievre, A.; Alouani, E.L.; Marmorino, F.; Pernot, S.; et al. (Annals of Oncology, 2024)